CytRx Corporation (CYTR)
-NasdaqCM 2.45 
0.02(0.81%) May 17, 4:00PM EDT
| Prev Close: | 2.47 |
|---|
| Open: | 2.43 |
|---|
| Bid: | 1.93 x 100 |
|---|
| Ask: | 2.95 x 400 |
|---|
| 1y Target Est: | 8.50 |
|---|
| Beta: | 1.63 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.35 - 2.48 |
|---|
| 52wk Range: | 1.59 - 5.50 |
|---|
| Volume: | 88,772 |
|---|
| Avg Vol (3m): | 152,654 |
|---|
| Market Cap: | 74.99M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.58 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CYTRX CORP FinancialsEDGAR Online Financials(Fri, May 17)
- CytRx Reports 2013 First Quarter Financial ResultsBusiness Wire(Thu, May 9)
- CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, May 9)
- CYTRX CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- CytRx Provides Update on Clinical ProgramsBusiness Wire(Wed, May 8)
- Right Time To Buy This Pharmaceutical Company?at Motley Fool(Tue, May 7)
- 3 Healthcare Stock Stories For Monday Investment Wellnessat Wall St. Cheat Sheet(Mon, May 6)
- CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue SarcomaBusiness Wire(Mon, May 6)
- A Tale Of Three Pharmaceuticals: Getting Exciting In 2013at Seeking Alpha(Mon, Apr 29)
- CytRx Announces Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue SarcomaBusiness Wire(Tue, Apr 23)
- 5 Stocks Poised for Breakoutsat TheStreet(Fri, Apr 19)
- Celsion Corp Director Buys 20K Shares and 4 Insider Trades to Noteat Wall St. Cheat Sheet(Fri, Mar 22)
- New Star Analyst Rankings for CytRx CorporationStarMine(Tue, Mar 12)
- CytRx to Present at the 25th Annual ROTH ConferenceBusiness Wire(Tue, Mar 12)
- CytRx Reports 2012 Financial ResultsBusiness Wire(Mon, Mar 11)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 755.99 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.75 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.16 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes two programs, aldoxorubicin and tamibarotene, which are in clinical development for cancer indications.
View More